{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:25Z","timestamp":1792801705996,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"General Project of Chongqing Science and Health Joint Medical Scientific Research Project","award":["2024MSXM177"],"award-info":[{"award-number":["2024MSXM177"]}]},{"name":"Future Medicine Youth Innovation Team Project of Chongqing Medical University","award":["W0081"],"award-info":[{"award-number":["W0081"]}],"id":[{"id":"https:\/\/ror.org\/017z00e58","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Key Project of Chongqing Science and Health Joint Medical Scientific Research Project","award":["2022ZDXM020"],"award-info":[{"award-number":["2022ZDXM020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00874-7","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:49:06Z","timestamp":1740728946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and validation of a nomogram to predict linezolid-induced thrombocytopenia in hospitalized adults"],"prefix":"10.1186","volume":"26","author":[{"given":"Ya","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peishu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"12","key":"874_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.21037\/atm.2018.06.28","volume":"6","author":"G Vrioni","year":"2018","unstructured":"Vrioni G, et al. MALDI-TOF mass spectrometry technology for detecting biomarkers of antimicrobial resistance: current achievements and future perspectives. Ann Transl Med. 2018;6(12):240.","journal-title":"Ann Transl Med"},{"issue":"2","key":"874_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1086\/345744","volume":"36","author":"MC Birmingham","year":"2003","unstructured":"Birmingham MC, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36(2):159\u201368.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"874_CR3","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1248\/bpb.b16-00427","volume":"39","author":"M Tajima","year":"2016","unstructured":"Tajima M, et al. Linezolid-Induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2. Biol Pharm Bull. 2016;39(11):1846\u201351.","journal-title":"Biol Pharm Bull"},{"issue":"7","key":"874_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/14740338.2018.1484106","volume":"17","author":"X Nie","year":"2018","unstructured":"Nie X, et al. Evaluation of reporting quality for observational studies using routinely collected health data in pharmacovigilance. Expert Opin Drug Saf. 2018;17(7):661\u20138.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"874_CR5","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1016\/j.clinthera.2009.10.017","volume":"31","author":"T Niwa","year":"2009","unstructured":"Niwa T, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126\u201333.","journal-title":"Clin Ther"},{"issue":"4","key":"874_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11096-014-9961-6","volume":"36","author":"R Hirano","year":"2014","unstructured":"Hirano R, et al. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36(4):795\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"874_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jac\/dkr522","volume":"67","author":"N Patel","year":"2012","unstructured":"Patel N, et al. A comparative evaluation of adverse platelet outcomes among Veterans\u2019 affairs patients receiving linezolid or Vancomycin. J Antimicrob Chemother. 2012;67(3):727\u201335.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"874_CR8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1086\/382356","volume":"38","author":"N Rao","year":"2004","unstructured":"Rao N, et al. Similar hematologic effects of long-term linezolid and Vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis. 2004;38(8):1058\u201364.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"874_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.4140\/TCP.n.2012.504","volume":"27","author":"S Lam","year":"2012","unstructured":"Lam S. Linezolid-associated thrombocytopenia. Consult Pharm. 2012;27(7):504\u20138.","journal-title":"Consult Pharm"},{"key":"874_CR10","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.12659\/AJCR.911362","volume":"19","author":"B Xiao","year":"2018","unstructured":"Xiao B, et al. Lactic acidosis and thrombocytopenia associated with linezolid therapy: A case report. Am J Case Rep. 2018;19:1117\u201320.","journal-title":"Am J Case Rep"},{"issue":"2","key":"874_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bcpt.13123","volume":"124","author":"GW Choi","year":"2019","unstructured":"Choi GW, et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol. 2019;124(2):228\u201334.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"10","key":"874_CR12","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1001\/jama.285.10.1291","volume":"285","author":"SL Green","year":"2001","unstructured":"Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA. 2001;285(10):1291.","journal-title":"JAMA"},{"issue":"4","key":"874_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2006.04.017","volume":"28","author":"YH Lin","year":"2006","unstructured":"Lin YH, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345\u201351.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"874_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1086\/498509","volume":"42","author":"VC Wu","year":"2006","unstructured":"Wu VC, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66\u201372.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"874_CR15","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1128\/AAC.01185-10","volume":"55","author":"T Sasaki","year":"2011","unstructured":"Sasaki T, et al. Population Pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother. 2011;55(5):1867\u201373.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"874_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00228-013-1585-6","volume":"70","author":"AP Cossu","year":"2014","unstructured":"Cossu AP, et al. Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature. Eur J Clin Pharmacol. 2014;70(1):23\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"874_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/jac\/dki202","volume":"56","author":"S Grau","year":"2005","unstructured":"Grau S, et al. Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother. 2005;56(2):440\u20131.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"874_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s15010-014-0674-5","volume":"42","author":"B Natsumoto","year":"2014","unstructured":"Natsumoto B, et al. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007\u201312.","journal-title":"Infection"},{"issue":"6","key":"874_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.curtheres.2012.07.002","volume":"73","author":"C Chen","year":"2012","unstructured":"Chen C, et al. Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73(6):195\u2013206.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"6","key":"874_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","volume":"33","author":"HY Dong","year":"2014","unstructured":"Dong HY, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction May reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2014;33(6):1029\u201335.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"874_CR21","doi-asserted-by":"publisher","first-page":"710099","DOI":"10.3389\/fphar.2022.710099","volume":"13","author":"L Duan","year":"2022","unstructured":"Duan L, et al. A regression model to predict linezolid induced thrombocytopenia in neonatal Sepsis patients: A Ten-Year retrospective cohort study. Front Pharmacol. 2022;13:710099.","journal-title":"Front Pharmacol"},{"issue":"9","key":"874_CR22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jiac.2022.05.004","volume":"28","author":"I Maray","year":"2022","unstructured":"Maray I, et al. Linezolid induced thrombocytopenia in critically ill patients: risk factors and development of a machine learning-based prediction model. J Infect Chemother. 2022;28(9):1249\u201354.","journal-title":"J Infect Chemother"},{"key":"874_CR23","doi-asserted-by":"crossref","unstructured":"Qin Y et al. Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients. Eur J Hosp Pharm. 2022.","DOI":"10.21203\/rs.3.rs-582799\/v1"},{"issue":"4","key":"874_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.pop.2016.07.008","volume":"43","author":"EJ Lee","year":"2016","unstructured":"Lee EJ, Lee AI. Thrombocytopenia Prim Care. 2016;43(4):543\u201357.","journal-title":"Thrombocytopenia Prim Care"},{"issue":"4","key":"874_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1378\/chest.13-0121","volume":"144","author":"DR Williamson","year":"2013","unstructured":"Williamson DR, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144(4):1207\u201315.","journal-title":"Chest"},{"issue":"3","key":"874_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1055\/s-0039-1697930","volume":"46","author":"E Danese","year":"2020","unstructured":"Danese E, et al. Drug-Induced thrombocytopenia: mechanisms and laboratory diagnostics. Semin Thromb Hemost. 2020;46(3):264\u201374.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"874_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/jcpt.12762","volume":"44","author":"HS Kim","year":"2019","unstructured":"Kim HS, et al. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study. J Clin Pharm Ther. 2019;44(1):84\u201390.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"874_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/jcpt.13287","volume":"46","author":"R Tanaka","year":"2021","unstructured":"Tanaka R, et al. A retrospective test for a possible relationship between linezolid-induced thrombocytopenia and hyponatraemia. J Clin Pharm Ther. 2021;46(2):343\u201351.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"874_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10096-019-03754-1","volume":"39","author":"J Cazavet","year":"2020","unstructured":"Cazavet J, et al. Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2020;39(3):527\u201338.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"874_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10156-010-0182-1","volume":"17","author":"Y Takahashi","year":"2011","unstructured":"Takahashi Y, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382\u20137.","journal-title":"J Infect Chemother"},{"issue":"10","key":"874_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3855\/jidc.10859","volume":"13","author":"E Kaya Kilic","year":"2019","unstructured":"Kaya Kilic E, et al. Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination. J Infect Dev Ctries. 2019;13(10):886\u201391.","journal-title":"J Infect Dev Ctries"},{"issue":"8","key":"874_CR32","first-page":"1136","volume":"29","author":"JG Slatter","year":"2001","unstructured":"Slatter JG, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos. 2001;29(8):1136\u201345.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"874_CR33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/jac\/dkg180","volume":"51","author":"DJ Stalker","year":"2003","unstructured":"Stalker DJ, et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an Oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother. 2003;51(5):1239\u201346.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"874_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijantimicag.2008.07.002","volume":"33","author":"K Matsumoto","year":"2009","unstructured":"Matsumoto K, et al. Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents. 2009;33(1):98\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"874_CR35","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/jac\/dkt133","volume":"68","author":"Y Nukui","year":"2013","unstructured":"Nukui Y, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128\u201333.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"874_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","volume":"42","author":"GG Rao","year":"2020","unstructured":"Rao GG, et al. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: A review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42(1):83\u201392.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"874_CR37","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","volume":"22","author":"Y Hanai","year":"2016","unstructured":"Hanai Y, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22(8):536\u201342.","journal-title":"J Infect Chemother"},{"key":"874_CR38","doi-asserted-by":"crossref","unstructured":"Crass RL, et al. Reappraisal of linezolid dosing in renal impairment to improve safety. Antimicrob Agents Chemother. 2019;63(8).","DOI":"10.1128\/AAC.00605-19"},{"issue":"1","key":"874_CR39","doi-asserted-by":"publisher","first-page":"26064","DOI":"10.1038\/s41598-024-77768-x","volume":"14","author":"H Zhao","year":"2024","unstructured":"Zhao H, et al. A nomogram incorporating linezolid and metabolite concentrations for predicting linezolid induced thrombocytopenia in patients with renal impairment. Sci Rep. 2024;14(1):26064.","journal-title":"Sci Rep"},{"issue":"8","key":"874_CR40","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/jac\/dks153","volume":"67","author":"F Pea","year":"2012","unstructured":"Pea F, et al. Therapeutic drug monitoring May improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(8):2034\u201342.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"874_CR41","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1517\/17425255.2016.1166204","volume":"12","author":"D Cattaneo","year":"2016","unstructured":"Cattaneo D, Alffenaar JW, Neely M. Drug monitoring and individual dose optimization of antimicrobial drugs: Oxazolidinones. Expert Opin Drug Metab Toxicol. 2016;12(5):533\u201344.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"874_CR42","doi-asserted-by":"crossref","unstructured":"Kawasuji H et al. Initially reduced linezolid dosing regimen to prevent thrombocytopenia in Hemodialysis patients. Antibiot (Basel). 2021;10(5).","DOI":"10.3390\/antibiotics10050496"},{"issue":"3","key":"874_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ccc.2016.02.003","volume":"32","author":"J Gallagher","year":"2016","unstructured":"Gallagher J, Biesboer AN, Killian AJ. Pharmacologic issues in liver disease. Crit Care Clin. 2016;32(3):397\u2013410.","journal-title":"Crit Care Clin"},{"issue":"6","key":"874_CR44","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1517\/17425255.2016.1170807","volume":"12","author":"P Sazdanovic","year":"2016","unstructured":"Sazdanovic P, et al. Pharmacokinetics of linezolid in critically ill patients. Expert Opin Drug Metab Toxicol. 2016;12(6):595\u2013600.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"874_CR45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ijantimicag.2017.06.023","volume":"50","author":"SG Wicha","year":"2017","unstructured":"Wicha SG, et al. Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a Pharmacokinetic pilot study. Int J Antimicrob Agents. 2017;50(4):557\u201363.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"874_CR46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1499-3872(15)60379-4","volume":"14","author":"YM Zhang","year":"2015","unstructured":"Zhang YM, et al. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid. Hepatobiliary Pancreat Dis Int. 2015;14(3):287\u201392.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"6","key":"874_CR47","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/FTD.0000000000000665","volume":"41","author":"S Luque","year":"2019","unstructured":"Luque S, et al. Linezolid dosing in patients with liver cirrhosis: standard dosing risk toxicity. Ther Drug Monit. 2019;41(6):732\u20139.","journal-title":"Ther Drug Monit"},{"key":"874_CR48","doi-asserted-by":"crossref","unstructured":"Zhang SH, et al. Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction. Antimicrob Agents Chemother. 2020;64(6).","DOI":"10.1128\/AAC.00133-20"},{"issue":"7","key":"874_CR49","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/j.1528-1167.2006.00587.x","volume":"47","author":"T Gerstner","year":"2006","unstructured":"Gerstner T, et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006;47(7):1136\u201343.","journal-title":"Epilepsia"},{"issue":"3","key":"874_CR50","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1528-1167.2007.01429.x","volume":"49","author":"W Nasreddine","year":"2008","unstructured":"Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008;49(3):438\u201345.","journal-title":"Epilepsia"},{"issue":"8","key":"874_CR51","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1592\/phco.21.11.1010.34517","volume":"21","author":"DJ Kuter","year":"2001","unstructured":"Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the Oxazolidinone linezolid. Pharmacotherapy. 2001;21(8):1010\u20133.","journal-title":"Pharmacotherapy"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00874-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00874-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00874-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:49:17Z","timestamp":1740728957000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00874-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00874-7","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of the First Affiliated Hospital of Army Medical University with a waiver of the requirement for informed consent (KY2023015) and adhered to the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}